Pharma Stocks
-
Assessing Ionis Pharmaceuticals After Positive Clinical Trial News and a 112% Rally in 2025
If you’re standing at the crossroads of whether to jump into Ionis Pharmaceuticals stock, you’re not alone. Investors are weighing…
Read More » -
What Do Analysts Think About Royalty Pharma Plc (RPRX)?
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most profitable biotech stocks to buy. On October 10, Morgan Stanley analyst…
Read More » -
Analysts Expect Breakeven For Evoke Pharma, Inc. (NASDAQ:EVOK) Before Long
Evoke Pharma, Inc. (NASDAQ:EVOK) is possibly approaching a major achievement in its business, so we would like to shine some…
Read More » -
Xenon Pharmaceuticals (XENE): Evaluating Valuation After Bringing on Veteran CFO Tucker Kelly
Xenon Pharmaceuticals (XENE) recently named Tucker Kelly as its new Chief Financial Officer, effective October 15. Kelly’s track record guiding…
Read More » -
Is New Phase 3 Data on Vimseltinib Changing the Investment Case for Ono Pharmaceutical (TSE:4528)?
Ono Pharmaceutical recently presented two-year efficacy and safety data from the MOTION Phase 3 study of vimseltinib in patients with…
Read More » -
Eli Lilly, Merck and Johnson & Johnson gain on strong pharma outlook
Sel Hardy, senior equity research analyst at CFRA, joins BNN Bloomberg to share her Hot Picks in pharma stocks. The…
Read More » -
A Look at Elanco Animal Health’s Valuation After Securing FDA Emergency Use Nod for Credelio
Elanco Animal Health (NYSE:ELAN) just secured the first Emergency Use Authorization from the U.S. FDA for Credelio to treat New…
Read More » -
The pullback in China’s biopharmaceutical stocks presents an attractive buying opportunity, with CSPC Pharmaceutical (01093.HK) and Sinopharm Group (01099.HK) as preferred picks.
The CLSA report notes that China’s biotechnology and innovative pharmaceuticals industry has experienced volatility, driven by previous price increases leading…
Read More » -
3 Healthcare Stocks That Are Screaming Deals Right Now
Key Points DaVita’s recession-resistant business is growing internationally, but shares continue to trade at a heavily discounted valuation. Merck could…
Read More » -
Phathom Pharmaceuticals Stock (PHAT) Opinions on Phase 3 VOQUEZNA Study Results
By: Quiver DiscussionTracker Posted: 2 hours ago / Oct. 26, 2025 2:02 p.m. UTC VOQUEZNA Data Sparks Interest: Recent chatter on…
Read More »
